Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 3 | 3 | — | — | 6 |
Ischemic stroke | D000083242 | — | — | 1 | 3 | 2 | — | — | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | — | 1 |
Cerebral infarction | D002544 | — | I63 | — | 1 | — | — | — | 1 |
Drug common name | Desmoteplase |
INN | desmoteplase |
Description | Desmoteplase is a novel, highly fibrin-specific "clot-busting" (thrombolytic) drug in development that reached phase III clinical trials. The Danish pharmaceutical company, Lundbeck, owns the worldwide rights to Desmoteplase. In 2009, two large trials (DIAS-3 and DIAS-4) were started to test it as a safe and effective treatment for patients with acute ischaemic stroke. After disappointing results in DIAS-3, DIAS-4 was terminated, and in December 2014 Lundbeck announced that they would stop the development of desmoteplase.
|
Classification | Enzyme |
Drug class | enzymes: tissue-type plasminogen activators |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2109084 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB04925 |
UNII ID | T36L245S3T (ChemIDplus, GSRS) |